Skip to main content
SpringerLink
Log in
Book cover

Chemical Proteomics pp 15–21Cite as

Chemical Proteomics in Drug Discovery

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 803))

Abstract

Real-world drug discovery and development remains a notoriously unproductive and increasingly uneconomical process even in the Omics era. The dominating paradigm in the industry continues to be target-based drug design, with an increased perception of the role of signaling pathways in homeostasis and in disease. Since proteins represent the major type of drug targets, proteomics-based approaches, which study proteins under relatively physiological conditions, have great potential if they can be reduced to practice such that they successfully complement the arsenal of drug discovery techniques. This chapter discusses examples of drug discovery processes where chemical proteomics-based assays using native endogenous proteins should have substantial impact.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Brown, D. (2007) Unfinished business: target-based drug discovery. Drug Discov. Today 12, 1007–1012.

    Article  PubMed  CAS  Google Scholar 

  2. Kola, I., and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715.

    Article  PubMed  CAS  Google Scholar 

  3. Fishman, M. C., and Porter, J. A. (2005) Pharmaceuticals: a new grammar for drug discovery. Nature 437, 491–493.

    Article  PubMed  CAS  Google Scholar 

  4. Hall, S. E. (2006) Chemoproteomics-driven drug discovery: addressing high attrition rates. Drug Discov. Today 11, 495–502.

    Article  PubMed  CAS  Google Scholar 

  5. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006) How many drug targets are there? Nat. Rev. Drug Discov. 5, 993–996.

    Article  PubMed  CAS  Google Scholar 

  6. Clamp, M., Fry, B., Kamal, M., Xie, X., Cuff, J., Lin, M. F., Kellis, M., Lindblad-Toh, K., and Lander, E. S. (2007) Distinguishing protein-coding and noncoding genes in the human genome. Proc. Natl. Acad. Sci. USA 104, 19428–19433.

    Article  PubMed  CAS  Google Scholar 

  7. Hopkins, A. L., and Groom, C. R. (2002) The druggable genome. Nat. Rev. Drug Discov. 1, 727–730.

    Article  PubMed  CAS  Google Scholar 

  8. Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S., and Schreiber, S. L. (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756–758.

    Article  PubMed  CAS  Google Scholar 

  9. Harding, M. W., Galat, A., Uehling, D. E., and Schreiber, S. L. (1989) A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341, 758–760.

    Article  PubMed  CAS  Google Scholar 

  10. Huang, S. M., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., Hild, M., Shi, X., Wilson, C. J., Mickanin, C., Myer, V., Fazal, A., Tomlinson, R., Serluca, F., Shao, W., Cheng, H., Shultz, M., Rau, C., Schirle, M., Schlegl, J., Ghidelli, S., Fawell, S., Lu, C., Curtis, D., Kirschner, M. W., Lengauer, C., Finan, P. M., Tallarico, J. A., Bouwmeester, T., Porter, J. A., Bauer, A., and Cong, F. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620.

    Article  PubMed  CAS  Google Scholar 

  11. Fleischer, T. C., Murphy, B. R., Flick, J. S., Terry-Lorenzo, R. T., Gao, Z. H., Davis, T., McKinnon, R., Ostanin, K., Willardsen, J. A., and Boniface, J. J. (2010) Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. Chem. Biol. 17, 659–664.

    Article  PubMed  CAS  Google Scholar 

  12. Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C. W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., White, J., Kirilovsky, J., Rice, C. M., Lora, J. M., Prinjha, R. K., Lee, K., and Tarakhovsky, A. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119–1123.

    Article  PubMed  CAS  Google Scholar 

  13. Fadden, P., Huang, K. H., Veal, J. M., Steed, P. M., Barabasz, A. F., Foley, B., Hu, M., Partridge, J. M., Rice, J., Scott, A., Dubois, L. G., Freed, T. A., Silinski, M. A., Barta, T. E., Hughes, P. F., Ommen, A., Ma, W., Smith, E. D., Spangenberg, A. W., Eaves, J., Hanson, G. J., Hinkley, L., Jenks, M., Lewis, M., Otto, J., Pronk, G. J., Verleysen, K., Haystead, T. A., and Hall, S. E. (2010) Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem. Biol. 17, 686–694.

    Article  PubMed  CAS  Google Scholar 

  14. Bantscheff, M., Hopf, C., Savitzki, M. M., Dittmann, A., Grandi, P., Michon, A. M. M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., Boesche, M., Delling, M., Dümpelfeld, B., Eberhard, D., Huthmacher, C., Mathieson, T., Poeckel, D., Strunk, K., Sweetman, G., Kruse, U., Neubauer, G., Ramsden, N., and Drewes, G. (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255–265.

    Google Scholar 

  15. Morphy, R., Kay, C., and Rankovic, Z. (2004) From magic bullets to designed multiple ligands. Drug Discov. Today 9, 641–651.

    Article  PubMed  CAS  Google Scholar 

  16. Kruse, U., Bantscheff, M., Drewes, G., and Hopf, C. (2008) Chemical and pathway ­proteomics: powerful tools for oncology drug discovery and personalized health care. Mol. Cell Proteomics. 7, 1887–1901.

    Article  PubMed  CAS  Google Scholar 

  17. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., and Handa H. (2010) Identification of a primary target of thalidomide teratogenicity. Science. 327, 1345–1350.

    Article  PubMed  CAS  Google Scholar 

  18. Fliri, A. F., Loging, W. T., Thadeio, P. F., and Volkmann, R. A. (2005) Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat. Chem. Biol. 1, 389–397.

    Article  PubMed  CAS  Google Scholar 

  19. Ong, S. E., Schenone, M., Margolin, A. A., Li, X., Do, K., Doud, M. K., Mani, D. R., Kuai, L., Wang, X., Wood, J. L., Tolliday, N. J., Koehler, A. N., Marcaurelle, L. A., Golub, T. R., Gould, R. J., Schreiber, S. L., and Carr, S. A. (2009) Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc. Natl. Acad. Sci. USA 106, 4617–4622.

    Article  PubMed  CAS  Google Scholar 

  20. Rix, U., and Superti-Furga, G. (2009) Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5, 616–624.

    Article  PubMed  CAS  Google Scholar 

  21. Sharma, K., Weber, C., Bairlein, M., Greff, Z., Keri, G., Cox, J., Olsen, J. V., and Daub, H. (2009) Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741–744.

    Article  PubMed  CAS  Google Scholar 

  22. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044.

    Article  PubMed  CAS  Google Scholar 

  23. Cravatt, B. F., Wright, A. T., and Kozarich, J. W. (2008) Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 77, 383–414.

    Article  PubMed  CAS  Google Scholar 

  24. Paulick, M. G., and Bogyo, M. (2008) Application of activity-based probes to the study of enzymes involved in cancer progression. Curr. Opin. Genet. Dev. 18, 97–106.

    Article  PubMed  CAS  Google Scholar 

  25. Haystead, T. A. (2006) The purinome, a complex mix of drug and toxicity targets. Curr. Top. Med. Chem. 6, 1117–1127.

    Article  PubMed  CAS  Google Scholar 

  26. Graves, P. R., Kwiek, J. J., Fadden, P., Ray, R., Hardeman, K., Coley, A. M., Foley, M., and Haystead, T. A. (2002) Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364–1372.

    Article  PubMed  CAS  Google Scholar 

  27. Borawski, J., Troke, P., Puyang, X., Gibaja, V., Zhao, S., Mickanin, C., Leighton-Davies, J., Wilson, C. J., Myer, V., Cornellataracido, I., Baryza, J., Tallarico, J., Joberty, G., Bantscheff, M., Schirle, M., Bouwmeester, T., Mathy, J. E., Lin, K., Compton, T., Labow, M., Wiedmann, B., and Gaither, L. A. (2009) Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 83, 10058–10074.

    Article  PubMed  CAS  Google Scholar 

  28. Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., and Waterfield, M. D. (2007) Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 404, 15–21.

    Article  PubMed  CAS  Google Scholar 

  29. Raijmakers, R., Dadvar, P., Pelletier, S., Gouw, J., Rumpel, K., and Heck, A. J. (2010) Target profiling of a small library of phosphodiesterase 5 (PDE5) inhibitors using chemical proteomics. ChemMedChem. 5, 1927–1936.

    Article  PubMed  CAS  Google Scholar 

  30. Patricelli, M. P., Szardenings, A. K., Liyanage, M., Nomanbhoy, T. K., Wu, M., Weissig, H., Aban, A., Chun, D., Tanner, S., and Kozarich, J. W. (2007) Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46, 350–358.

    Article  PubMed  CAS  Google Scholar 

  31. Luo, Y., Fischer, J. J., Baessler, O. Y., Schrey, A. K., Ungewiss, J., Glinski, M., Sefkow, M., Dreger, M., and Koester, H. (2010) GDP-capture compound – a novel tool for the profiling of GTPases in pro- and eukaryotes by capture compound mass spectrometry (CCMS). J. Proteomics. 73, 815–819.

    Article  PubMed  CAS  Google Scholar 

  32. Dalhoff, C., Huben, M., Lenz, T., Poot, P., Nordhoff, E., Koster, H., and Weinhold, E. (2010) Synthesis of S-adenosyl-L-homocysteine capture compounds for selective photoinduced isolation of methyltransferases. Chembiochem. 11, 256–265.

    Article  PubMed  CAS  Google Scholar 

  33. Ge, X., Wakim, B., and Sem, D. S. (2008) Chemical proteomics-based drug design: target and antitarget fishing with a catechol-rhodanine privileged scaffold for NAD(P)(H) binding proteins. J. Med. Chem. 51, 4571–4580.

    Article  PubMed  CAS  Google Scholar 

  34. Kato, D., Boatright, K. M., Berger, A. B., Nazif, T., Blum, G., Ryan, C., Chehade, K. A., Salvesen, G. S., and Bogyo, M. (2005) Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1, 33–38.

    Article  PubMed  CAS  Google Scholar 

  35. Berkers, C. R., Verdoes, M., Lichtman, E., Fiebiger, E., Kessler, B. M., Anderson, K. C., Ploegh, H. L., Ovaa, H., and Galardy, P. J. (2005) Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat. Methods 2, 357–362.

    Article  PubMed  CAS  Google Scholar 

  36. Salisbury, C. M., and Cravatt, B. F. (2007) Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc. Natl. Acad. Sci. USA 104, 1171–1176.

    Article  PubMed  CAS  Google Scholar 

  37. Nomura, D. K., Dix, M. M., and Cravatt, B. F. (2010) Activity-based protein profiling for biochemical pathway discovery in cancer. Nat. Rev. Cancer 10, 630–638.

    Article  PubMed  CAS  Google Scholar 

  38. Edgington, L. E., Berger, A. B., Blum, G., Albrow, V. E., Paulick, M. G., Lineberry, N., and Bogyo, M. (2009) Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat. Med. 15, 967–973.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cellzome AG, Heidelberg, Germany

    Gerard Drewes

Authors
  1. Gerard Drewes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerard Drewes .

Editor information

Editors and Affiliations

  1. CellZome AG, Meyerhofstrasse 1, Heidelberg, 69117, Germany

    Gerard Drewes

  2. CellZome AG, Meyerhofstrasse 1, Heidelberg, 69117, Germany

    Marcus Bantscheff

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Drewes, G. (2012). Chemical Proteomics in Drug Discovery. In: Drewes, G., Bantscheff, M. (eds) Chemical Proteomics. Methods in Molecular Biology, vol 803. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-364-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-364-6_2

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-363-9

  • Online ISBN: 978-1-61779-364-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation